NCT03087890View on ClinicalTrials.gov

Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria

PHASE4CompletedINTERVENTIONAL
Enrollment

537

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

July 25, 2019

Study Completion Date

July 25, 2019

Conditions
HIV-1-infectionPneumocystis PneumoniaOpportunistic InfectionsPreventive TherapyAntibiotic Side Effect
Interventions
DRUG

Cotrimoxazole

Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks

DRUG

Placebo

Patients will receive 2 tablets placebo daily for 48 weeks

Trial Locations (6)

Unknown

Amana Regional Referral Hospital, Dar es Salaam

Mbagala District Hospital, Dar es Salaam

Mnazimmoja Health Centre, Dar es Salaam

Mwananyamala Regional Referral Hospital, Dar es Salaam

Pasada Upendano, Dar es Salaam

Temeke Regional Referral Hospital, Dar es Salaam

All Listed Sponsors
collaborator

Haukeland University Hospital

OTHER

collaborator

Muhimbili University of Health and Allied Sciences

OTHER

collaborator

Helse Vest

OTHER

lead

University of Bergen

OTHER

NCT03087890 - Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria | Biotech Hunter | Biotech Hunter